CN120617264A - 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼 - Google Patents

用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼

Info

Publication number
CN120617264A
CN120617264A CN202511059211.7A CN202511059211A CN120617264A CN 120617264 A CN120617264 A CN 120617264A CN 202511059211 A CN202511059211 A CN 202511059211A CN 120617264 A CN120617264 A CN 120617264A
Authority
CN
China
Prior art keywords
pharmaceutical composition
lou064
patient
treatment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511059211.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·巴塔查里亚
B·比耶特
B·岑尼
G·格拉哈姆
M·容克
C·洛舍
K·拉普
善金贤
J·B·齐勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority claimed from CN202380022664.5A external-priority patent/CN118742308A/zh
Publication of CN120617264A publication Critical patent/CN120617264A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202511059211.7A 2022-02-28 2023-02-27 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼 Pending CN120617264A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263314572P 2022-02-28 2022-02-28
US63/314,572 2022-02-28
US202263369016P 2022-07-21 2022-07-21
US63/369,016 2022-07-21
PCT/IB2023/051787 WO2023161887A1 (en) 2022-02-28 2023-02-27 Remibrutinib for use in the treatment of hidradenitis suppurativa
CN202380022664.5A CN118742308A (zh) 2022-02-28 2023-02-27 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202380022664.5A Division CN118742308A (zh) 2022-02-28 2023-02-27 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼

Publications (1)

Publication Number Publication Date
CN120617264A true CN120617264A (zh) 2025-09-12

Family

ID=85570288

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202511059211.7A Pending CN120617264A (zh) 2022-02-28 2023-02-27 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼

Country Status (11)

Country Link
US (1) US20250099465A1 (https=)
EP (1) EP4486346A1 (https=)
JP (2) JP7696006B2 (https=)
KR (1) KR20240155278A (https=)
CN (1) CN120617264A (https=)
AU (1) AU2023225222A1 (https=)
CA (1) CA3251002A1 (https=)
IL (1) IL314205A (https=)
MX (1) MX2024010392A (https=)
TW (1) TW202342048A (https=)
WO (1) WO2023161887A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234779A1 (en) * 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor
CN112512527A (zh) * 2018-09-12 2021-03-16 杭州索元生物医药股份有限公司 恩扎妥林和btk抑制剂的组合及其用途
US20210205313A1 (en) * 2020-01-08 2021-07-08 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
LT3380465T (lt) 2015-11-26 2020-11-10 Novartis Ag Diamino piridino dariniai
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JP7007374B2 (ja) 2016-09-23 2022-01-24 ノバルティス アーゲー 腱及び／又は靭帯損傷に使用するためのインダゾール化合物
MX2021014161A (es) 2019-05-23 2022-01-04 Novartis Ag Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
HRP20251001T1 (hr) 2019-05-23 2025-10-24 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije
TWI905371B (zh) 2021-01-26 2025-11-21 瑞士商諾華公司 藥物組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512527A (zh) * 2018-09-12 2021-03-16 杭州索元生物医药股份有限公司 恩扎妥林和btk抑制剂的组合及其用途
WO2020234779A1 (en) * 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor
CN113840821A (zh) * 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型
US20210205313A1 (en) * 2020-01-08 2021-07-08 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUMBERGER BETH E. 等: "Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis", INFLAMMATION RESEARCH, vol. 69, no. 10, 13 July 2020 (2020-07-13), pages 967 *

Also Published As

Publication number Publication date
EP4486346A1 (en) 2025-01-08
JP2024511938A (ja) 2024-03-18
JP7696006B2 (ja) 2025-06-19
WO2023161887A1 (en) 2023-08-31
IL314205A (en) 2024-09-01
TW202342048A (zh) 2023-11-01
CA3251002A1 (en) 2023-08-31
MX2024010392A (es) 2024-09-06
US20250099465A1 (en) 2025-03-27
KR20240155278A (ko) 2024-10-28
AU2023225222A1 (en) 2024-07-25
JP2025134747A (ja) 2025-09-17

Similar Documents

Publication Publication Date Title
Sá et al. Inflammasomes and dermatology
AU2020280272B2 (en) Methods of treating Chronic Spontaneous Urticaria using a Bruton's tyrosine kinase inhibitor
Zhou et al. Karacoline, identified by network pharmacology, reduces degradation of the extracellular matrix in intervertebral disc degeneration via the NF-κB signaling pathway
JP2024511141A (ja) オリスミラストによる化膿性汗腺炎の治療
JP2025134747A (ja) 化膿性汗腺炎の治療における使用のためのレミブルチニブ
JP2024525515A (ja) がんの予防用又は治療用の医薬組成物
TW202304458A (zh) 用於黑色素瘤之組合治療
CN118742308A (zh) 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼
JP7594124B2 (ja) Ｌｏｕ０６４を使用した治療の方法
US20140127295A1 (en) Compositions, process of preparation of said compositions and method of treating inflammatory diseases
EA051701B1 (ru) Ремибрутиниб для применения в лечении гнойного гидраденита
JP2025513474A (ja) 好中球性皮膚疾患の治療
CN118401242A (zh) 使用lou064的治疗方法
TW202502379A (zh) 抗il-36r抗體用於治療化膿性汗腺炎（hs）之用途
CN117479936A (zh) 用奥瑞司特治疗化脓性汗腺炎
Williams et al. 294 Milk, Microbes, and Monoclonals: How Biologic Therapy Might Shape Maternal–Infant Microbiome Dynamics in Hidradenitis Suppurativa
Marren et al. THU0173 Pregnancy Outcomes in the Tofacitinib RA Safety Database Through April 2014
Keystone et al. THU0190 Long-Term Impact of Delaying Combination Therapy with Adalimumab Plus Methotrexate by 2 Years in Patients with Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial
Spellman et al. 290 Clinical Study of RLS-1496 Topical Cream: Targeting Cellular Senescence in Patients with Mild to Moderate Plaque Psoriasis, Atopic Dermatitis, and Aged Skin
Acosta et al. 4CPS-156 Safety profile of apremilast in psoriasis and psoriatic arthritis
KR20250150635A (ko) 인자 b 억제제의 사용 방법
EA051816B1 (ru) Способы лечения с применением lou064
El Rakaawi et al. THU0397 Efficacy of pamidronate in children with osteogenesis imperfecta: An open prospective study
HK40061328B (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
HK40061328A (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination